Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New treatment increases life time expectancy of patients suffering from advanced liver cancer

05.06.2007
A trial designed and co-led by Dr. Jordi Bruix, head of the Hepatology Service of Hospital Clínic- IDIBAPS (Barcelona) and Dr. Josep Maria Llovet, ICREA researcher of the Hepatic Oncology Group, are planning a new treatment which increases the overall survival of patients suffering from advanced liver cancer.

The results of this study, called SHARP (Sorafenib HCC –hepatocellular carcinoma– Assessment Randomized Protocol) allow overall survival (OS) and time to symptom progression (TTSP) comparison between patients who were administered Sorafenib orally, (developed by BAYER) and another group of patients, treated with placebo. The results presented by Clínic-IDIBAPS investigators have been hand selected to be included on the Best of ASCO program. This is an educational initiative that condenses highlights from ASCO’s Annual Meeting into a 1½ day program.

Results are consistent and significant. Overall survival of patients treated with Sorafenib was in average 10.7 months compared to 7.9 months within the group administered placebo. Thus, this treatment increases overall survival by more than 40% if compared to the placebo group. Furthermore, no differences were observed in the severe side effects rate between the treatment’s two modalities. Obtained data imply an unprecedented therapeutic progress in the treatment of advanced liver cancer and involve a shift in this disease’s paradigm. This treatment gives new hope for patients who, until now, could neither beneficiate from curative effects of therapies nor hope for survival improvement. From a scientific point of view, this drug, which delays tumor progression and improves survival, will be the base for future further research.

The SHARP study, an international phase III trial, lead by Hospital Clínic in collaboration with Mount Sinai, where Dr. Llovet is head of the Hepatic Cancer Research Program, started 5 years ago and included a total of 602 patients from 110 centers from the USA, South America, Europe, Australia and New Zealand. All participating patients suffered from advanced liver cancer and had not received any kind of therapy prior to the study.

... more about:
»ASCO »Sorafenib »liver cancer »progression »survival

As a consequence of the good results showed by patients treated with Sorafenib, researchers decided to end the study ahead of schedule in order to administer the drug also to the rest of patients participating in this trial.

Liver cancer and Sorafenib

Primary liver cancer, also known as hepatocellular carcinoma, is the most common of liver cancers. This is the fifth most common cancer worldwide and, in Spain, this disease has an incidence of 10-11 new cases per 100,000 inhabitants per year. The most affected patients are those suffering from acute cirrhosis caused by hepatitis B/ C infections or by excessive alcohol consumption.

Until now, patients suffering from liver cancer in an initial phase have benefited from procedures like resection, transplantation or ablation. Unfortunately, more than 60% of cases of liver cancer are detected in an advanced phase, making chemoembolisation the only available treatment. Chemoembolisation could only be applied to 15% of patients, and there was no other effective treatment for the rest of patients.

Sorafenib blocks a cellular cycle signal pathway, preventing not only the proliferation of tumor cells but also the formation of blood vessels supporting the tumor. Therefore, it delays tumor progression and, as a consequence, improves survival. This implies a hopeful change for patients since until now, treatments tried to eradicate the disease, whereas these new type of agents try to stop the progression of the disease. If new drugs or new combinations of drugs achieve total inhibition of cancer progression, cancer as a whole, and liver cancer in particular, will not necessarily give rise to death.

Hospital Clínic at ASCO

The ASCO Annual Meeting, celebrated this year in Chicago from June 01 – 05 is considered to be the world’s most important event for the whole scientific community conducting research on issues related to cancer, which has more than 30,000 researchers. Every year thousands of articles from all over the world are presented at ASCO, reflecting the last clinical and translational research progress within the areas of prevention, diagnosis and treatment of cancer.

The important role of Hospital Clínic’s presence at the ASCO Annual Meeting is centered in the presence of Dr. Jordi Bruix and Dr. Josep María Llovet from the Hepatic Oncology Group of Hospital Clínic-IDIBAPS, who have participated in today’s plenary session, 04th June at 1 p.m. The plenary session is the central event of this conference, only holding the presentation of results of four chosen research works.

Furthermore, Dr. Joan Bladé and Dr. Laura Rosiñol, both from the Haematooncology Group of Hospital Clínic-IDIBAPS participated in two oral presentations about two new multiple myeloma studies.

These events strengthen Hospital Clinic’s commitment in being an oncological reference hospital not only for the development of translations researches, but also for patient health care.

Àlex Argemí Saburit | alfa
Further information:
http://www.hospitalclinic.org

Further reports about: ASCO Sorafenib liver cancer progression survival

More articles from Life Sciences:

nachricht The birth of a new protein
20.10.2017 | University of Arizona

nachricht Building New Moss Factories
20.10.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>